Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults
April 28, 2023
April 28, 2023
MedinCell: SAIVE Study data to be presented at ECCMID 2023 Euronext: MEDCL
April 17, 2023
April 17, 2023
MedinCell announces the initiation of coverage of its stock by Portzamparc – BNP Paribas Group
March 27, 2023
March 27, 2023
MedinCell receives “Prime” ISS ESG rating as a recognition of the embedment of Corporate Social Responsibility across the Company
February 23, 2023
February 23, 2023
Initiation of the Phase 3 study for the second long-acting injectable antipsychotic using MedinCell’s technology (program mdc-TJK)
January 24, 2023
January 24, 2023
MedinCell announces the initiation of coverage of its stock by TPICAP Midcap
January 5, 2023
January 5, 2023
MedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population
January 5, 2023
January 5, 2023
Publication of the 2023 financial calendar
January 3, 2023
January 3, 2023
MedinCell publishes its financial results for the first semester of 2022-2023
December 6, 2022
December 6, 2022
Additional US$ 4 million received for next development steps of MedinCell’s 6-month active injectable bioresorbable subcutaneous contraceptive
November 30, 2022
November 30, 2022
Details of the financing agreement signed by MedinCell and the European Investment Bank (EIB)
November 23, 2022
November 23, 2022
France : EIB and MedinCell sign a new €40 million loan agreement to support development of innovative treatments
November 23, 2022
November 23, 2022
Contacts
Medincell
David Heuzé
Head of Corporate and Financial Communications, and ESG
